Fig 1: T334 phosphorylation modulates 53BP1 interaction with PTIP and RIF1 and influences DSB repair dynamics.(A) Coimmunoprecipitation assay of 53BP1 with PTIP and RIF1 in WT U2OS cells before and 1 hour after ionizing radiation (IR; 6 Gy). Relative intensities of (B) 53BP1 and (C) T334 phospho-53BP1 (pT334-53BP1) bands were quantified by ImageJ at 0 hours and 1 hour after IR (n = 3). Data represent mean ± SEM. Band intensities for 53BP1 and pT334-53BP1 were first normalized to their respective input levels and then further normalized to the input levels of PTIP and RIF1-FLAG signals across the 0 Gy and 6 Gy conditions. Values are mean ± SEM. Statistical significance was determined by 2-way ANOVA followed by Tukey’s multiple comparisons test. ***P < 0.001; ****P < 0.0001.
Fig 2: Effects of GSK3B-mediated phosphorylation at T334 on 53BP1 functions in NHEJ repair of DSBs cont.(A) Representative images of 53BP1–/– U2OS cells reconstituted with HA-tagged WT or T334A 53BP1 and irradiated with 6Gy IR to induce DNA damage. Cells were stained for 53BP1(HA) and RIF1. Percentage of U2OS cells with or without GSK3B inhibitor that were positive for RIF1. n = 3. Absolute number of RIF1 foci per U2OS cell with or without GSK3B inhibitor. n = 3. Relative RIF1 foci intensity in U2OS cells with or without GSK3B inhibitor. n = 3. (B) Representative images of 53BP1–/– U2OS cells reconstituted with HA-tagged WT or T334A 53BP1 and irradiated with 6 Gy to induce DNA damage. Cells were stained for 53BP1(HA) and PTIP. Percentage of U2OS cells with or without GSK3B inhibitor that were positive for PTIP. n = 3. Absolute number of PTIP foci per U2OS cell with or without GSK3B inhibitor. n = 3. Relative PTIP foci intensity in U2OS cells with or without GSK3B inhibitor. n = 3. Relative intensity was calculated for each cell by the Image J software. Statistical significance was assessed using 1- and 2-way ANOVA with Tukey’s test. *P < 0.05; **P < 0.01; ***P < 0.001. Magnification ×65.
Fig 3: Structural modeling comparison of PTIP and PTIP576.(A) Alignments of hexameric repeats within Exons 12–14 of the carboxyl terminus of PTIP576. Top line: Basic residues (+) within exons (e) 12–14; 2nd line: N-terminal e12 sequence successfully employed to derive homologies via data base; alignments below: exon 12 is aligned with 3 candidates that share identity (boxed): Gln-Pro-Val-His-Arg-Leu (QPVHRL) which derive from MEIS (Myeloid Ecotropic viral Integration Site 1), [35]; the LDLR (Low-Density Lipoprotein Receptor) [36]; and TRIL (TLR4-Interactor with Leucine-rich repeats) [37]. (B) Predicted structure of PTIP for BRCT 3–6, color-coded by pLDDT scores. (C) Disorder score plot calculated by AIUPred. Scores above 0.5 (indicated by a gray line) represent predicted disordered region. (D) Predicted structure of PTIP576. Only the central BRCT domains (3 and 4) are shown, along with the frameshifted residues, corresponding to residues 770 – 820 in PTIP. Ribbon Diagram generated by Chimera X.
Fig 4: T334 phosphorylation modulates 53BP1 interaction with PTIP and RIF1 and influences DSB repair dynamics cont.Reciprocal coimmunoprecipitation assay of 53BP1 and PTIP and RIF1 with or without IR in WT and T334A reconstituted 53BP1–/– U2OS cells before and after IR (6 Gy) (left panel). Quantification of Co-IP bands intensity at 0 hours and 1 hour. n = 3. Values are mean ± SEM. Statistical significance was determined by 2-way ANOVA followed by Tukey’s multiple comparisons test. *P < 0.05; ****P < 0.0001.
Fig 5: Cartoon illustrating the frame shift and alternative pre-mRNA splicing that generates PTIP and its isoform PTIP576.The amino acid sequence shown represents the C-terminal 50 amino acids of PTIP576 that are altered compared to those of PTIP due to a two-base frameshift mutation. These amino acids are encoded by exon 12 (position 1–30), exon 13 (position 31–44), and exon 14 (position 45–50). The lowercase letters indicate the amino acids that are altered from those encoded by the frameshifted PTIP DNA due to a subsequent suppressor mutation in PTIP576.
Supplier Page from Abcam for Anti-PTIP antibody